INHL001

INHL001 is a preclinical small molecule drug candidate developed by Lee's Pharmaceutical for the treatment of respiratory viral infections. It is an inhaled formulation designed to act as an RNA-directed RNA polymerase (RdRp) inhibitor, a mechanism that interferes with the replication of various RNA viruses. The drug is part of Lee's Pharmaceutical's specialized inhalation platform, which focuses on delivering therapeutic agents directly to the respiratory tract via nebulization. While the code INHL001 was historically associated with the company's amikacin inhalation project in earlier pipeline iterations, current company data identifies it as a distinct preclinical antiviral program for respiratory diseases.